BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
Provided By GlobeNewswire
Last update: Sep 10, 2025
BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p<.05)
Complete resolution of agitation was significantly higher with BXCL501 compared to placebo across agitation episode severity (p<.0001)
Read more at globenewswire.com
